cannabidiol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5288 13956-29-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cannabidiol
  • GWP42003-P
  • epidiolex
The precise mechanisms by which cannabidiol exerts its anticonvulsant effect in humans are unknown. Cannabidiol does not appear to exert its anticonvulsant effects through interaction with cannabinoid receptors.
  • Molecular weight: 314.47
  • Formula: C21H30O2
  • CLOGP: 6.94
  • LIPINSKI: None
  • HAC: 2
  • HDO: 2
  • TPSA: 40.46
  • ALOGS: -4.40
  • ROTB: 6

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.70 g O

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 6.69 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 13.55 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 23.82 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Sept. 19, 2019 EMA GW Pharma (International) B.V.
June 25, 2018 FDA GW RESEARCH LTD

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Device related thrombosis 108.69 23.01 24 3693 1283 50600124
Drug resistance 92.49 23.01 39 3678 18950 50582457
Multiple-drug resistance 86.50 23.01 24 3693 3290 50598117
Blood pressure diastolic decreased 73.57 23.01 32 3685 16749 50584658
Nail disorder 61.18 23.01 24 3693 9684 50591723
Large intestine polyp 60.22 23.01 22 3695 7310 50594097
Seizure 51.95 23.01 53 3664 117821 50483586
Tonic convulsion 47.69 23.01 12 3705 1127 50600280
Body temperature decreased 46.11 23.01 23 3694 16372 50585035
Heart rate irregular 45.31 23.01 24 3693 19336 50582071
Drug interaction 42.36 23.01 62 3655 199559 50401848
Blood pressure systolic increased 41.20 23.01 28 3689 35421 50565986
Cystic fibrosis 40.84 23.01 13 3704 2851 50598556
Skin exfoliation 40.14 23.01 27 3690 33585 50567822
Off label use 39.78 23.01 99 3618 474327 50127080
Breast cancer metastatic 36.60 23.01 17 3700 10347 50591060
Therapeutic product effective for unapproved indication 34.62 23.01 6 3711 88 50601319
Drug level increased 34.43 23.01 20 3697 19248 50582159
Hip fracture 33.79 23.01 22 3695 25909 50575498
Metastases to bone 30.37 23.01 18 3699 17977 50583430
Therapeutic product ineffective for unapproved indication 29.75 23.01 6 3711 206 50601201
Skin reaction 26.10 23.01 14 3703 11554 50589853
Metastases to liver 26.05 23.01 17 3700 20087 50581320
Productive cough 23.72 23.01 24 3693 52670 50548737
Pyelonephritis chronic 23.63 23.01 5 3712 218 50601189
Diarrhoea 23.40 23.01 95 3622 588381 50013026

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Seizure 100.07 29.37 65 1740 93058 29479664
Drug interaction 64.39 29.37 69 1736 197316 29375406
Behaviour disorder 44.37 29.37 14 1791 3602 29569120
Social avoidant behaviour 38.64 29.37 12 1793 2930 29569792
Alcohol intolerance 32.74 29.37 7 1798 388 29572334

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 107.65 22.91 134 4730 361949 64131919
Device related thrombosis 96.89 22.91 24 4840 2061 64491807
Multiple-drug resistance 94.00 22.91 30 4834 6472 64487396
Drug resistance 68.70 22.91 39 4825 35063 64458805
Blood pressure diastolic decreased 67.01 22.91 33 4831 22268 64471600
Seizure 66.53 22.91 72 4792 166820 64327048
Nail disorder 63.31 22.91 24 4840 8600 64485268
Large intestine polyp 51.31 22.91 22 4842 10815 64483053
Tonic convulsion 50.45 22.91 14 4850 1867 64492001
Off label use 48.71 22.91 130 4734 632676 63861192
Blood pressure systolic increased 47.20 22.91 35 4829 49418 64444450
Heart rate irregular 44.51 22.91 27 4837 27386 64466482
Behaviour disorder 42.32 22.91 15 4849 4447 64489421
Breast cancer metastatic 42.19 22.91 17 4847 7152 64486716
Body temperature decreased 35.70 22.91 23 4841 25905 64467963
Social avoidant behaviour 34.59 22.91 13 4851 4544 64489324
Therapeutic product effective for unapproved indication 33.41 22.91 6 4858 106 64493762
Therapeutic product ineffective for unapproved indication 32.61 22.91 6 4858 122 64493746
Hip fracture 32.36 22.91 22 4842 27077 64466791
Alcohol intolerance 31.20 22.91 7 4857 391 64493477
Skin exfoliation 30.45 22.91 26 4838 44859 64449009
Somnolence 28.16 22.91 53 4811 203592 64290276
Blood pressure diastolic abnormal 28.14 22.91 15 4849 11902 64481966
Metastases to bone 27.81 22.91 18 4846 20417 64473451
Drug ineffective 27.25 22.91 130 4734 840117 63653751
Drug level increased 25.66 22.91 21 4843 34175 64459693
Metastases to liver 25.23 22.91 18 4846 23923 64469945
Cough 25.06 22.91 64 4800 302084 64191784
Diarrhoea 25 22.91 114 4750 722590 63771278
Status epilepticus 24.48 22.91 17 4847 21646 64472222
Hypersomnia 23.52 22.91 16 4848 19701 64474167
Intentional product use issue 23.03 22.91 32 4832 95332 64398536

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N03AX24 NERVOUS SYSTEM
ANTIEPILEPTICS
ANTIEPILEPTICS
Other antiepileptics
FDA CS M0003267 Cannabinoids
MeSH PA D000927 Anticonvulsants
MeSH PA D002491 Central Nervous System Agents
FDA MoA N0000182138 Cytochrome P450 1A2 Inhibitors
FDA MoA N0000182139 Cytochrome P450 2B6 Inhibitors
FDA MoA N0000182140 Cytochrome P450 2C19 Inhibitors
FDA MoA N0000185504 Cytochrome P450 2C9 Inhibitors
FDA MoA N0000187062 Cytochrome P450 2C8 Inhibitors
FDA MoA N0000187064 Cytochrome P450 2B6 Inducers
FDA MoA N0000191273 UGT2B7 Inhibitors
FDA MoA N0000191278 UGT1A9 Inhibitors
CHEBI has role CHEBI:76924 plant metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Lennox-Gastaut syndrome indication 230418006
Severe myoclonic epilepsy in infancy indication 230437002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.34 acidic
pKa2 11.34 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 11154516 June 17, 2034 USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 11154516 June 17, 2034 USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 10092525 June 17, 2035 USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH DRAVET SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 10111840 June 17, 2035 USE FOR THE TREATMENT OF ATONIC SEIZURES IN PATIENTS WITH DRAVET SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 10111840 June 17, 2035 USE FOR THE TREATMENT OF ATONIC SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 10137095 June 17, 2035 USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 10137095 June 17, 2035 USE IN COMBINATION WITH CLOBAZAM FOR TREATMENT OF DROP SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 10603288 June 17, 2035 USE FOR REDUCING CONVULSIVE SEIZURE FREQUENCY IN PATIENTS WITH DRAVET SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 10603288 June 17, 2035 USE FOR REDUCING CONVULSIVE SEIZURE FREQUENCY IN PATIENTS WITH LENNOX GASTAUT SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 10603288 June 17, 2035 USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 10603288 June 17, 2035 USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 10709671 June 17, 2035 USE FOR THE TREATMENT OF FOCAL SEIZURES IN PATIENTS WITH DRAVET SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 10709674 June 17, 2035 USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 10709674 June 17, 2035 USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 10849860 June 17, 2035 USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH DRAVET SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 10849860 June 17, 2035 USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 10966939 June 17, 2035 USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 10966939 June 17, 2035 USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 11311498 June 17, 2035 USE FOR THE TREATMENT OF ABSENCE SEIZURES IN PATIENTS WITH DRAVET SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 11311498 June 17, 2035 USE FOR THE TREATMENT OF ABSENCE SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 9949937 June 17, 2035 USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 9956183 June 17, 2035 USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME WHO HAVE BEEN PREVIOUSLY TREATED WITH CLOBAZAM
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 9956183 June 17, 2035 USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME WHO HAVE BEEN PREVIOUSLY TREATED WITH CLOBAZAM
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 9956184 June 17, 2035 USE IN COMBINATION WITH CLOBAZAM FOR TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 9956185 June 17, 2035 USE FOR THE TREATMENT OF CONVULSIVE SEIZURES IN PATIENTS WITH DRAVET SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 9956186 June 17, 2035 USE FOR THE TREATMENT OF CONVULSIVE SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 10918608 Oct. 14, 2035 USE FOR REDUCING SEIZURE FREQUENCY IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 10918608 Oct. 14, 2035 USE FOR THE TREATMENT OF GENERALIZED SEIZURES OR FOCAL SEIZURES WITH IMPAIRMENT IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 10918608 Oct. 14, 2035 USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 11065209 Oct. 14, 2035 USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 11096905 Oct. 14, 2035 USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 11096905 Oct. 14, 2035 USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 11207292 April 26, 2039 USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 11207292 April 26, 2039 USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 11207292 April 26, 2039 USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL 11160795 March 1, 2041 USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX IN PATIENTS TAKING EVEROLIMUS

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL July 31, 2023 NEW PATIENT POPULATION
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL Sept. 28, 2023 NEW CHEMICAL ENTITY
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL Sept. 28, 2025 INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) OR DRAVET SYNDROME (DS) IN PATIENTS 2 YEARS OF AGE AND OLDER
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL July 31, 2027 TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) OR DRAVET SYNDROME (DS) IN PATIENTS BETWEEN 1 AND 2 YEARS OF AGE
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL July 31, 2027 TREATMENT OF SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX (TSC) IN PATIENTS 1 YEAR OF AGE AND OLDER

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Transient receptor potential cation channel subfamily V member 1 Ion channel INHIBITOR IC50 5.43 CHEMBL SCIENTIFIC LITERATURE
G-protein coupled receptor 55 GPCR ANTAGONIST EC50 6.35 CHEMBL SCIENTIFIC LITERATURE
D(1A) dopamine receptor GPCR Ki 5.57 CHEMBL
5-hydroxytryptamine receptor 1A GPCR EC50 5.10 CHEMBL
5-hydroxytryptamine receptor 2C GPCR Ki 5.96 CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 5.50 CHEMBL
Alpha-2C adrenergic receptor GPCR Ki 5.43 CHEMBL
Kappa-type opioid receptor GPCR Ki 5.64 CHEMBL
Delta-type opioid receptor GPCR Ki 5.19 CHEMBL
Cannabinoid receptor 2 GPCR Ki 5.54 CHEMBL
Histamine H3 receptor GPCR Ki 5.51 CHEMBL
N-arachidonyl glycine receptor GPCR AGONIST EC50 4.29 IUPHAR
Cannabinoid receptor 1 GPCR Ki 5.62 CHEMBL
Transmembrane protein 97 Enzyme Ki 5.47 CHEMBL
Transient receptor potential cation channel subfamily V member 2 Ion channel ACTIVATOR EC50 4.50 IUPHAR
Mu-type opioid receptor GPCR Ki 5.89 CHEMBL
Cannabinoid receptor 1 GPCR Ki 5.90 CHEMBL
Cannabinoid receptor 2 GPCR Ki 6.64 CHEMBL
Fatty-acid amide hydrolase 1 Enzyme IC50 4.27 CHEMBL
Transient receptor potential cation channel subfamily M member 8 Ion channel IC50 5.55 CHEMBL
Transient receptor potential cation channel subfamily V member 2 Ion channel ACTIVATOR EC50 5.43 IUPHAR
Transient receptor potential cation channel subfamily A member 1 Ion channel IC50 6.35 CHEMBL
Heat sensitive channel TRPV3 Unclassified EC50 6.29 CHEMBL
Transient receptor potential cation channel subfamily V member 4, TrpV4 Unclassified EC50 6.05 CHEMBL
5-hydroxytryptamine receptor 2A GPCR EC50 4.50 CHEMBL

External reference:

IDSource
19GBJ60SN5 UNII
C0006863 UMLSCUI
CHEBI:69478 CHEBI
P0T PDB_CHEM_ID
CHEMBL190461 ChEMBL_ID
644019 PUBCHEM_CID
DB09061 DRUGBANK_ID
D002185 MESH_DESCRIPTOR_UI
D10915 KEGG_DRUG
4150 IUPHAR_LIGAND_ID
2045371 RXNORM
20468 MMSL
291103 MMSL
d08919 MMSL
771981005 SNOMEDCT_US
96223000 SNOMEDCT_US
4036658 VANDF
010751 NDDF
10423 INN_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Epidiolex HUMAN PRESCRIPTION DRUG LABEL 1 70127-100 SOLUTION 100 mg ORAL NDA 31 sections
Epidiolex HUMAN PRESCRIPTION DRUG LABEL 1 70127-100 SOLUTION 100 mg ORAL NDA 31 sections
NanoCDB HUMAN OTC DRUG LABEL 1 70658-122 SOLUTION/ DROPS 1.94 g BUCCAL Export only 8 sections
leafPro CBDmed Oil FS QP 3% HUMAN OTC DRUG LABEL 1 73674-001 OIL 3 g ORAL unapproved drug other 15 sections
leafPro CBDmed Oil FS QP 5% HUMAN OTC DRUG LABEL 1 73674-002 OIL 5 g ORAL unapproved drug other 15 sections
leafPro CBDmed Oil FS QP 20% HUMAN OTC DRUG LABEL 1 73674-005 OIL 20 g ORAL unapproved drug other 15 sections
leafPro CBDmed Oil T-FS QD 3% HUMAN OTC DRUG LABEL 1 73674-020 OIL 3 g ORAL unapproved drug other 15 sections
leafPro CBDmed Oil T-FS QD 5% HUMAN OTC DRUG LABEL 1 73674-021 OIL 5 g ORAL unapproved drug other 15 sections
leafPro CBDmed Oil T-FS QD 20% HUMAN OTC DRUG LABEL 1 73674-024 OIL 20 g ORAL unapproved drug other 15 sections
leafPro CBDmed Softgels FS QP 20 HUMAN OTC DRUG LABEL 1 73674-052 CAPSULE, LIQUID FILLED 20 mg ORAL unapproved drug other 15 sections
leafPro CBDmed Softgels T-FS QD 20 HUMAN OTC DRUG LABEL 1 73674-061 CAPSULE, LIQUID FILLED 20 mg ORAL unapproved drug other 15 sections
Kaydia Patch HUMAN OTC DRUG LABEL 3 75140-002 PATCH 0.15 g TOPICAL unapproved drug other 8 sections